DEBRA Research GmbH | Finanzwire

Basculer en Français

9475	Companies
185456	Keywords
117803	Articles
99310	Press releases

Home
Companies
DEBRA Research GmbH

BRIEF

published on 10/29/2025 at 13:05, 1 month 7 days ago

DEBRA Research Supports Eliksa Therapeutics in Developing ELK-003 for EB-Related Eye Conditions

Epidermolysis Bullosa DEBRA Research Eliksa Therapeutics ELK-003 Biological Eye Drop
PRESS RELEASE

published on 10/29/2025 at 13:00, 1 month 7 days ago

DEBRA Research Invests in Eliksa Therapeutics to Advance ELK-003, a Biological Eye Drop for Epidermolysis Bullosa-Related Ocular Complications
DEBRA Research invests in Eliksa Therapeutics to advance ELK-003, a biological eye drop for Epidermolysis Bullosa-related ocular complications, supported by a syndicate of mission-driven organizations

Rare Diseases Ocular Complications DEBRA Research Eliksa Therapeutics ELK-003
BRIEF

published on 09/22/2025 at 12:35, 2 months 13 days ago

DEBRA Research and Nonsense Therapeutics Form ReadOn Therapeutics

Patient Advocacy Biotech Innovation Epidermolysis Bullosa ReadOn Therapeutics Nonsense Mutations
PRESS RELEASE

published on 09/22/2025 at 12:30, 2 months 13 days ago

DEBRA Research and Nonsense Therapeutics Launch ReadOn Therapeutics to Accelerate Novel Therapies for Epidermolysis Bullosa
DEBRA Research and Nonsense Therapeutics form ReadOn Therapeutics to accelerate therapies for Epidermolysis Bullosa. Focus on dystrophic EB and nonsense mutations. Innovative non-profit model

Epidermolysis Bullosa DEBRA Research ReadOn Therapeutics Nonsense Therapeutics Dystrophic EB
BRIEF

published on 08/07/2025 at 09:05, 3 months 29 days ago

DEBRA Research Teams with Queen Mary University for EB Drug Development

Drug Development Preclinical Research Epidermolysis Bullosa DEBRA Research Queen Mary University
PRESS RELEASE

published on 08/07/2025 at 09:00, 3 months 29 days ago

DEBRA Research Collaborates with Queen Mary University of London to Advance Drug Development for Epidermolysis bullosa
DEBRA Research collaborates with Queen Mary University of London to advance drug development for Epidermolysis bullosa. Partnership aims to accelerate research and innovation in tackling this rare skin condition

Drug Development Preclinical Research Epidermolysis Bullosa DEBRA Research Queen Mary University
BRIEF

published on 05/28/2025 at 09:05, 6 months 8 days ago

DEBRA Research and Dermaliq Join Forces for Epidermolysis Bullosa Treatment

Strategic Collaboration Epidermolysis Bullosa DEBRA Research Dermaliq Technology Topical Treatments
PRESS RELEASE

published on 05/28/2025 at 09:00, 6 months 8 days ago

DEBRA Research and Dermaliq Enter into a Strategic Collaboration to Advance Cutaneous Drug Delivery for Epidermolysis Bullosa
DEBRA Research and Dermaliq partner to advance cutaneous drug delivery for Epidermolysis Bullosa, focusing on innovative topical treatments and therapies using hyliQ technology

Epidermolysis Bullosa DEBRA Research Dermaliq Cutaneous Drug Delivery HyliQ Technology
BRIEF

published on 04/29/2025 at 10:05, 7 months 6 days ago

DEBRA Research Invests in Nova Anchora for Advancing Epidermolysis Bullosa Therapy

Investment Epidermolysis Bullosa DEBRA Research Nova Anchora Protein Therapy
PRESS RELEASE

published on 04/29/2025 at 10:00, 7 months 6 days ago

DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
DEBRA Research announces impact investment into Nova Anchora to advance protein therapy for Epidermolysis Bullosa. Global investors support development of NvA-011 for rare skin disorder treatment

Impact Investment Epidermolysis Bullosa DEBRA Research Nova Anchora Protein Therapy

Accesswire

Published on 12/05/2025 at 02:35, 11 hours 23 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 28 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 58 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 53 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 58 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:45, 12 minutes ago

BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 58 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 58 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 52 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 57 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre

Les Echos

Published on 12/05/2025 at 08:45, 5 hours 13 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 58 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 20 hours 13 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 20 hours 13 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE